



## Antimicrobial Utilisation Surveillance in Australian Hospitals

### **Tasmania – Statewide antimicrobial benchmarking report for acute inpatient aggregate usage rates**

**July 2023 – December 2023**

Antibacterial utilisation rates provided in this report are calculated using the number of defined daily doses (DDDs) of the antibacterial class consumed each month per 1,000 occupied bed days.

Contributing hospitals are assigned to Australian Institute for Health and Welfare (AIHW) defined peer groups.<sup>1</sup> Contributing hospitals can find their de-identifying code via the NAUSP Portal 'Maintain My Hospital' drop-down menu.

DDD values for each antimicrobial are assigned by the World Health Organization based on the “assumed average maintenance dose per day for the main indication in adults”. DDDs are reviewed annually by the WHO as dosing recommendations change over time. For more information refer to:


[https://www.whocc.no/atc\\_ddd\\_methodology/purpose\\_of\\_the\\_atc\\_ddd\\_system/](https://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system/).

The chart below presents the acute aggregated antibacterial usage rates for the respective contributing hospitals over the six-month period from 1 July 2023 to 31 December 2023. Unless otherwise specified, the aggregate rates include all acute care areas of the hospital, excluding usage in the emergency department and the operating theatre.

---

<sup>1</sup> AIHW. *Hospital resources 2017-18: Australian hospital statistics*. Available from <https://www.aihw.gov.au/reports/hospitals/hospital-resources-2017-18-ahs/data>

**Chart 1: Total hospital antibacterial usage rates (DDD/1000 OBD) in NAUSP contributor hospitals, by peer group, Tasmania, July-December 2023 (excludes Emergency Department and Operating Theatre)**



Alimentary antibiotics = rifaximin, fidaxomicin. \*Other = amphenicols, antimycotics, combinations for eradication of *Helicobacter pylori*, monobactams, nitrofurans, linezolid, daptomycin, other cephalosporins, polymyxins, rifamycins, second-generation cephalosporins, steroids, streptogramins and streptomycin.

This report includes data from the following 5 hospitals in Tasmania:

Calvary Lenah Valley Hospital  
Calvary St. John's Hospital  
Hobart Private Hospital  
Launceston General Hospital  
Mersey Community Hospital  
North West Regional Hospital  
Royal Hobart Hospital

*Disclaimer: Data presented in this report were correct at the time of publication. As additional hospitals join NAUSP, retrospective data are included. Data may change when quality assurance processes identify the need for data updates.*

The National Antimicrobial Utilisation Surveillance Program (NAUSP) is funded by the Commonwealth Department of Health and Aged Care. NAUSP is administered by Antimicrobial Programs, Communicable Disease Control Branch, Department for Health and Wellbeing, Government of South Australia. All individual hospital data contributed to this program will remain de-identified unless otherwise agreed in writing. Aggregated data may be provided to all contributors, the ACSQHC and the Commonwealth.

<b>ANTIBACTERIAL CLASSES</b>			
<b>Alimentary antibiotics</b>	fidaxomicin	<b>Lincosamides</b>	clindamycin
	paromomycin		lincomycin
	rifaximin		azithromycin
<b>Aminoglycosides</b>	amikacin	<b>Macrolides</b>	clarithromycin
	gentamycin		erythromycin
	neomycin		roxithromycin
	tobramycin		spiramycin
<b><math>\beta</math>-lactamase inhibitor combinations</b>	amoxicillin - clavulanate		<b>Monobactams</b>
	piperacillin - tazobactam	<b>Nitrofurans derivatives</b>	nitrofurantoin
<b><math>\beta</math>-lactamase resistant penicillins</b>	dicloxacillin	<b>Polymyxins</b>	colistin
	flucloxacillin		polymyxin B
<b><math>\beta</math>-lactamase sensitive penicillins</b>	benzathine benzylpenicillin	<b>Second-generation cephalosporins</b>	cefaclor
	benzylpenicillin		cefamandole
	phenoxymethylpenicillin		cefotetan
	procaine benzylpenicillin		cefoxitin
<b>Carbapenems</b>	doripenem		cefuroxime
	ertapenem	<b>Steroid antibacterials</b>	fusidic acid
	imipenem - cilastatin	<b>Streptogramins</b>	pristinamycin
	meropenem	<b>Streptomycins</b>	streptomycin
	meropenem - vaborbactam	<b>Sulfonamide-trimethoprim combinations</b>	sulfamethoxazole - trimethoprim
<b>Extended-spectrum penicillins</b>	amoxicillin	<b>Tetracyclines</b>	doxycycline
	ampicillin		minocycline
	pivmecillinam		tetracycline
	temocillin		tigecycline
<b>First-generation cephalosporins</b>	cefalexin		<b>Third-generation cephalosporins</b>
	cefalotin	cefotaxime	
	cefazolin	ceftazidime	
<b>Fluoroquinolones</b>	ciprofloxacin	ceftazidime - avibactam	
	levofloxacin	ceftriaxone	
	moxifloxacin	<b>Trimethoprim</b>	trimethoprim
	norfloxacin	<b>Other (including other cephalosporins and penems)</b>	ceftaroline fosamil
<b>Fourth-generation cephalosporins</b>	cefepime		ceftolozane - tazobactam
	ceftazidime		daptomycin
<b>Glycopeptides</b>	dalbavancin		faropenem
	oritavancin		fosfomicin
	teicoplanin		linezolid
	vancomycin		rifampicin
<b>Imidazole derivatives</b>	metronidazole	tedizolid	
<b>Intermediate-acting sulfonamides</b>	sulfadiazine		